Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 14, 2023
Reporting Period: Event date December 14, 2023; Signed December 18, 2023.
Context: The Company is an emerging growth company incorporated in Nevada. This filing reports the entry into a material definitive agreement regarding the extension of its poison pill rights plan.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly a disclosure of a corporate governance agreement.
Material Changes
- Rights Agreement Extension: The Company entered into Amendment No. 3 to its Rights Agreement with VStock Transfer, LLC.
- New Expiration Date: The expiration of the Rights Agreement was extended from December 30, 2023, to December 30, 2024.
- Administrative Updates: The amendment updated the notices authorized by the Rights Agreement.
- Historical Context: This follows previous amendments in 2021 and 2022 that extended the agreement's term.
Guidance, Outlook, and Risks
Management Commentary: The filing provides no forward-looking guidance, financial outlook, or management commentary beyond the description of the amendment.
Risks and Contingencies: The filing notes that the Rights are subject to the provisions of the Rights Agreement as amended. No specific new risks or contingencies are detailed in this text, other than the standard implication of maintaining a shareholder rights plan.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the full text of Amendment No. 3 attached as Exhibit 4.1 to confirm specific terms regarding the rights plan.
- Confirm the current status of the Company's cash position and runway, as this filing does not provide liquidity updates.
- Review the Company's most recent 10-K or 10-Q for financial performance metrics not included in this 8-K.
- Monitor for any future filings related to the expiration or further extension of the Rights Agreement in December 2024.